Read + Share
Goto Y. Editorial comment to real-world outcomes of pembrolizumab for platinum refractory
advanced urothelial carcinoma: Efficacy, safety, and evidence for trial-unfit
patients. Int J Urol 2023;30:704.
PMID: 36482811
|
 |
|
Goto Y. Editorial comment to real-world outcomes of pembrolizumab for platinum refractory
advanced urothelial carcinoma: Efficacy, safety, and evidence for trial-unfit
patients. Int J Urol 2023;30:704.
PMID: 36482811
|
|
|
|